Disruptive innovation investor Cathie Wood recently invested in clinical-stage biotech company Intellia Therapeutics (NTLA). Cathie Wood's Ark Investment Management strategically bought 560,600 shares of the gene-editing therapy firm, showing confidence in Intellia’s growth prospects.
There are positive analyst sentiments surrounding the firm's pioneering therapies, which might become hugely successful in the future. So, should you consider buying NTLA stock now?
